Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton’s tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL). METHODS: Patients with relapsed/refractory PCNS...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Yoshitaka, Nagane, Motoo, Mishima, Kazuhiko, Terui, Yasuhito, Arakawa, Yoshiki, Yonezawa, Hajime, Asai, Katsunori, Fukuhara, Noriko, Sugiyama, Kazuhiko, Shinojima, Naoki, Kitagawa, Junsaku, Aoi, Arata, Nishikawa, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850159/
https://www.ncbi.nlm.nih.gov/pubmed/32583848
http://dx.doi.org/10.1093/neuonc/noaa145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850159/
https://www.ncbi.nlm.nih.gov/pubmed/32583848
http://dx.doi.org/10.1093/neuonc/noaa145

Ejemplares similares